Key result
Oral nafazatrom reduces myocardial ischemia size ~45% versus vehicle control after coronary occlusion.
Why the study?
The effects of oral nafazatrom pretreatment on myocardial ischemia during acute coronary artery occlusion were not well characterized.
Does oral nafazatrom pretreatment reduce myocardial ischemia size and hemodynamic compromise in a rabbit heart model of acute coronary artery occlusion?
Population
Rabbit hearts undergoing 6-hour LAD occlusion
Comparison
Oral nafazatrom pretreatment vs drug-vehicle controls
Design
Preclinical experimental study
Follow-up
6 hours
Authors
Loading...
Nafazatrom effects in rabbits do not alter clinical practice; leaves open whether lipoxygenase inhibition merits human ischemia trials.
Does oral nafazatrom pretreatment reduce myocardial ischemia size and hemodynamic compromise in a rabbit heart model of acute coronary artery occlusion?
Absolute Event Rate: 45% vs 82%
p-value: p=<0.02
In a rabbit model, nafazatrom pretreatment significantly reduced myocardial ischemia size and prevented most hemodynamic changes following acute coronary artery occlusion.
Volker B. Fiedler (1984) studied Acute Myocardial Ischemia. Nafazatrom vs. Drug-vehicle control was evaluated on Ischemia size (percentage of LAD perfusion region at risk) (p=<0.02). Oral nafazatrom pretreatment reduced the ischemic portion of the LAD perfusion region at risk compared to vehicle control (45% vs 82%, p<0.02) in rabbit hearts during 6-hour LAD occlusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: